Skip to contentB
Bone Biologics Corp
B
BBLGBone Biologics Corp Q3 2020 · 10-Q
Revenue$0.00$0.00derivedno prior Q3 2019 on file Net Income-$394.05K-$394.05KN/M vs Q3 2019 EPS Diluted-$0.14-$0.14N/M vs Q3 2019 Operating Income-$145,823N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bone Biologics Corp · CIK 1419554 · Engraved from SEC EDGAR
Operating Cash Flowderived-$72,228N/M ended Sep 30, 2020 · filed Apr 15, 2021 · 197 d after period end